Evaluating Safety and Effectiveness of Dostarlimab and LB-100 for Recurrent Ovarian Clear Cell Carcinoma

What this Trial Is About

Researchers are evaluating the combination of dostarlimab and LB-100 in patients with recurrent ovarian clear cell carcinoma. This study aims to estimate overall survival at 6 and 12 months, describe immune-related side effects, and assess tumor response and progression using modified RECIST v1.1 criteria. It also explores biological markers such as PP2A activity, mismatch repair protein expression, and circulating tumor DNA levels for correlation with treatment response. Participants receive dostarlimab by vein over about 30 minutes on Day 1 of each cycle and LB-100 by vein on Days 1 through 3. The first doses are given over about 2 hours, with later doses possibly shortened to around 30 minutes. The study includes repeated treatment cycles with careful monitoring of tumor changes and immune responses. During the study, participants undergo tumor biopsies and blood sample collection to analyze immune and molecular changes. Safety is monitored by tracking adverse events graded by standard criteria. Researchers measure overall survival, tumor response rates, progression-free survival, and duration of response. The study lasts up to approximately one year with ongoing assessments to understand treatment effects and safety.

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100